The following trials provide information to treat various types of cardiovascular diseases, both for ongoing and completed clinical trials. For more information on this therapy area please click here.
- collapse A phase I, single-centre, open, randomized, two-way crossover study to evaluate the pharmacokinetics of the extended-release test formulation of AZD0837 compared to the extended-release AZD0837 reference formulation after repeated dosing in healthy volunteers
- collapse A single-blind, randomised, placebo-controlled, parallel-group, single centre phase I study to assess the safety, tolerability and pharmacokinetics of extended-release tablets AZD0837 after single and repeated oral administration to young healthy male Japanese subjects
- collapse A controlled, randomized, parellel, multi-centre feasibility study of the oral direct thrombin inhibitor, AZD0837, given as ER formulation, in the prevention of stroke and systolic embolic events in patients with atrial fibrillation, who are appropriate for but unable/unwilling to take VKA therapy.
- collapse Long-term treatment with the oral direct thrombin inhibitor AZD0837, compared to Vitamin-K antagonists, as stroke prevention in patients with non-valvular atrial fibrillation and one or more risk factors for stroke and systemic embolic events. A 5-year follow-up study.
- collapse An open, single centre pharmacokinetic (phase 1) study of the biliary excretion of AZD0837 and metabolites following a single dose of [3H] AZD0837 given in the duodenum via a Loc-I-Gut catheter to young healthy male subjects
- collapse An open, randomised, cross-over, single centre pharmacokinetic (phase I) study of the biliary excretion following single doses of AZD0837, given in the duodenum via a Loc-I-Gut catheter, alone or in combination with ketoconazole (once daily for 4 days), to young healthy male subjects
- collapse A Controlled, Randomized, Parallel, Multicentre Study to Assess Safety and Tolerability of the Oral Direct Thrombin Inhibitor AZD0837, given as an Extended-release Formulation, in the Prevention of Stroke and Systemic Embolic Events in Patients with Atrial Fibrillation
- collapse 18-Week, Multicenter, Randomized, Double-Blind 3b Trial to Evaluate Efficacy/Safety of Saxagliptin in Combo With Metformin XR 1500mg vs Metformin Uptitrated to 2000mg in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control After Diet/Exercise and a Stable Dose of Metformin XR 1500mg
- collapse A 24-Week National, Multi-centre, Randomized, Parallel-group, Double-blind, Placebo-controlled, Phase IIIb study in India to Evaluate the Efficacy and Safety of Saxagliptin in Adult Patients with Type 2 Diabetes who have Inadequate Glycaemic Control with Diet and Exercise.
- collapse A Randomised, Open-label, Single-Centre, Phase I, Crossover Study to Evaluate the Effect of AZD6482, Compared with Clopidogrel, on Bleeding Time in Healthy Volunteers Receiving Low-Dose ASA
